Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Bora Acquires Six US Brand Product Licenses, Rights
Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Product Name : Zestril
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2023
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Aztiq Buys 17% Stake in Alvogen US
Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.
Product Name : Zestril
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market
Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2020
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
